SCHEMBL30444863

SCHEMBL30444863

CCOC(=O)c1nonc1C1CC1(F)F

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ HPGD P15428 2/20 0.37
▸ CACNA1F O60840 2/20 0.36
▸ CACNA1D Q01668 2/20 0.36
▸ CACNA1S Q13698 2/20 0.36
▸ CACNA1C Q13936 2/20 0.36
▸ CYP1A2 P05177 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30999029 0.84 HTT (0.38) HTTKDM4EMAPTMEN1ALOX15
SCHEMBL22213866 0.78 HTT (0.42) HTTKDM4EMAPTMEN1ALOX15
SCHEMBL31054856 0.78 — —
SCHEMBL31054928 0.78 — —
SCHEMBL30999070 0.76 ALDH1A1 (0.41) HTTKDM4EMAPTMEN1ALOX15
SCHEMBL13382297 0.71 HTT (0.49) HTTKDM4EMAPTMEN1ALOX15
SCHEMBL23112644 0.70 KDM4E (0.41) HTTKDM4EMAPTMEN1ALOX15
SCHEMBL13815989 0.69 HTT (0.47) HTTKDM4EMAPTMEN1ALOX15
SCHEMBL28243333 0.69 KDM4E (0.49) HTTKDM4EMAPTMEN1ALOX15
SCHEMBL29253007 0.68 MAPT (0.34) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4408847-A1 IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS Janssen Pharmaceutica NV (BE) 2024-08-07 — — EP disclosed
WO-2023049887-A1 IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-03-30 — — WO disclosed
Send feedback